Stifel Maintains Hold Rating on Staar

On September 13, 2023, Stifel analyst Thomas Stephan reaffirmed his stance on Staar Surgical (NASDAQ:STAA), maintaining a Hold rating and a price target of $45. His analysis suggests that the stock is expected to track the overall market performance, indicating that it is neither advisable to buy nor sell the stock currently. It is worth noting that Stephan initially initiated coverage on Staar Surgical with a Hold rating on December 28, 2022.

STAA stock had a mixed performance on September 13, 2023. The stock opened at $44.66, slightly lower than the previous close of $44.90. Throughout the day, the stock traded within a range of $44.66 to $45.13. The volume for the day was 3,343 shares, significantly lower than the average volume of 850,221 shares over the past three months

STAA has a market capitalization of $2.1 billion, indicating its significance in the market. The company has shown strong earnings growth in the past year, with a growth rate of +55.61%. However, the earnings growth for this year has declined by -26.02%. Looking ahead, the company is expected to experience positive earnings growth over the next five years, with a projected growth rate of +30.00%.

In terms of revenue growth, STAA has performed well, with a growth rate of +23.40% in the last year. The price-to-earnings (P/E) ratio for STAA is 89.7, which suggests that the stock may be overvalued compared to its earnings. The price-to-sales ratio is 8.43, indicating that investors are willing to pay a premium for the company’s sales. The price-to-book ratio is 6.36, which suggests that the stock may be trading at a higher price relative to its book value.

https://beststocks.com/stifel-analyst-maintains-hold-rating-on-staar/